Home Companies What’s taking the Akari Therapeutics Plc (AKTX) stock to new heights?

What’s taking the Akari Therapeutics Plc (AKTX) stock to new heights?

Akari Therapeutics, Plc (Nasdaq: AKTX) a clinical-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases, confirmed that the U.S. Food and Drug Administration has granted Fast Track designation to nomacopan to treat patients affected with BP.  AKTX stock surged adjacent to the news.

At last check-in current trading, shares of Akari Therapeutics Plc (AKTX) were up 3.85% at $2.43. The price range of the company’s shares was between $2.31 and $2.38. It traded 9.19 million shares, which was above its daily average of 0.39 million shares over 100 days. The company had an earnings per share ratio of -0.63.


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


About Akari Therapeutics

Nomacopan has seen fast track to facilitate the development and treatment of serious conditions such as BP, and provide the patient with the drug as early as possible. Nomacopan receiving Fast Track could provide repeated meetings with FDA to review the drug’s development plan which may be inclusive of the design of the proposed clinical trials, and adequate data required for further approval.

A positive result to treat BP could potentially open up various other dermatological illnesses for treatment with nomacopan, including hidradenitis suppurativa, epidermolysis bullosa acquisita, and mucous membrane pemphigoid. Akari’s leading drug, Nomacopan is a C5 complement inhibitor that particularly binds to and inhibits leukotriene B4 (LTB4) activity.

BP is a severe orphan autoimmune disease that causes blistering and has no approved methods of treatment in the US and Europe.  The disease especially targets the elderly and firsthand treatment includes steroids and immunosuppressants for six months which may cause several side effects and a threefold increase in mortality in the BP-treated demographic.

BP is expected to have almost 120,000 patients in U.S. and EU5 with 75% of the patient population consisting of moderate and severe cases. In BP patients no adequate evidence is present that terminal complement activation has a major role in driving the illness. Furthermore, FDA approval of the Investigational New Drug Application (IND) allows clinical facilities to open in U.S. and Europe in mid-2021.

Conclusion

FDA approval of Akari Therapeutics manufactured drug nomacopan has peaked investor interest with AKTX surging at last check. Fast track of the drug may open several avenues for treatment of several diseases with most patients reporting moderate to severe cases.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

What Explains MOGO Stock Going Up Today?

The Mogo Inc. (NASDAQ: MOGO) stock has gained 5.04% to $8.55 in premarket trading today. Mogo stock finished last trading day at $8.14, down...

Zynga Inc. (ZNGA) stock rises in the Pre-Market: What’s going on?

Zynga Inc. (ZNGA) announced its first-quarter 2021 financial results after which the ZNGA stock happened to be green after underperformance in the last trade....

American Shared Hospital Services (AMS) Stock Continues to Soar Following Unprecedent Volumes Being Traded

American Shared Hospital Services (AMS) stock prices surged by 30.51% as of market close on May 5th, 2021, bringing the price per share up...

James River Group Holdings Ltd. (NASDAQ: JRVR) stock falls during pre-market. Why is it so?

James River Group Holdings Ltd. (NASDAQ: JRVR) stock plunged by 1.67% at last close while the JRVR stock continued decline by 25.74% at last...

Aviat Networks, Inc. (AVNW) Stock Trending Up After Promising Financial Reports for Most Recent Quarter

Aviat Networks, Inc. (AVNW) stock prices were up 3.81% as of market close on May 5th 2021, bringing the price per share up to...

Ambev S.A. (ABEV) Stock Trends Up Following Highly Promising Earnings Call for Q4 2020

Ambev S.A. (ABEV) stock prices were up 10.3943% shortly after the market opened on May 6th, 2021, bringing the price per share up to...

Sally Beauty Holdings (NYSE:SBH) stock surged in the current trading session; here’s why

In the current trading session, Sally Beauty Holdings Inc. (SBH) stock had surged by 19.69% to $24.25 at the time of writing. SBH stock...

Moderna Inc. (NASDAQ: MRNA) stock declines during current market. Let’s figure out why?

Moderna Inc. (NASDAQ: MRNA) stock falls by 5.31% in the current market trading after MRNA has announced its financial results for Q1 2021. Moderna...

Related News

Ambev S.A. (ABEV) Stock Trends Up Following Highly Promising Earnings Call for Q4 2020

Ambev S.A. (ABEV) stock prices were up 10.3943% shortly after the market opened on May 6th, 2021, bringing the price per share up to...

The Salem Media Group Inc. (NASDAQ:SALM) stock surged in the current trading session; here’s why

At the last check, in the current trading session, the Salem Media Group Inc. (SALM) stock surged by 6.29% to the price of $2.23....

AzurRx BioPharma Inc. (NASDAQ: AZRX) stock plunges in the current market trading. What is happening?

AzurRx BioPharma Inc. (NASDAQ: AZRX) stock falls by 8.93% at last check during the current market trading. Related to this decline in AZRX stock...

Is It Because The Stock of Communications Systems, Inc. (JCS) Is Climbing 111% Pre-Market?

In pre-market session today, Communications Systems, Inc. (JCS) shares have been rising aggressively. As of 09:16 a.m. EST, the stock was at a rise...

When Buying Condor Hospitality Trust Inc. (AMEX:CDOR), you need to consider this metric

Condor Hospitality Trust, Inc. (NYSE: CDOR) is a real estate investment trust focused on owning mid-scale and upscale hotels with premium brands in the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Insider Watchlist

Important Earnings

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.